Early Identification May Reduce Sepsis Severity and Economic Burden

Sepsis severity and cost of care linked to timing of diagnosis

Sepsis management remains a significant global healthcare challenge. In the U.S., sepsis is related to 970,000 hospitalizations annually, and the incidence of sepsis continues to rise each year.1 It is, by far, the costliest condition facing the country’s healthcare system, and timing of diagnosis is critical in terms of patient outcomes and economic impact. 

Using retrospective observational analysis of de-identified data, researchers set out to characterize the burden, outcomes and costs associated with sepsis patient care in U.S. hospitals. The study featured database information for patients over 18 years old with a hospital discharge diagnosis code of sepsis between January 1, 2010, and September 30, 2016. The authors also analyzed hospital billing records. 

In total, researchers evaluated records for approximately 2.5 million patients, with a mean age of 65 years. They found an overall mortality rate of 12.5%, with higher mortality rates occurring in more severe sepsis cases. Not only did mortality rates rise with sepsis severity (5.6% for patients with sepsis without organ dysfunction compared to 34.2% for patients with septic shock), but also costs increased significantly. When sepsis was present at admission, related costs were $18,023 versus $51,022 for cases where sepsis was not present at admission. The authors conclude that methods to improve early identification of sepsis may help to reduce the severity and economic impact of sepsis in the U.S. 
Patient hand in hospital bed

Journal Article Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level

Examine retrospective data from 2.5 million sepsis patients to learn more about the economic and human impact of this health crisis.

Read article

Referenced in This Article

1Paoli, CJ et al. “Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level.” Crit Care Med 2018; 46:1889-97.

Article featured in the Journal of Critical Care Medicine.

You may also be interested in:

Access SARS-CoV-2 IgG Antibody Test 
Laboratory studies show that to identify an immune response against the SARS-CoV-2 coronavirus, it is important to target the right antibodies. The Access SARS-CoV-2 IgG assay detects antibodies to the receptor-binding domain of the coronavirus spike protein, which may be important for assessing humoral and cellular immunity, based on laboratory studies. Learn more about this assay, which is available for Access 2, DxI 600 and DxI 800 immunoassay analyzers

Resources to Help in Navigating the SARS-CoV-2 Virus Pandemic 
The SARS-CoV-2 virus and the COVID-19 disease have disrupted the everyday lives of men, women and children around the world. Watch videos and access curated resources developed to help you in understanding, and managing, the SARS-CoV-2 virus pandemic.